Combining Atezolizumab and Bevacizumab with Proton Radiotherapy for Liver Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of combining Atezolizumab and Bevacizumab with proton radiotherapy in patients with unresectable hepatocellular carcinoma (HCC). The approach aims to enhance the objective response rate and progression-free survival by targeting the cancer with both immunotherapy and localized radiation. Participants must have a confirmed diagnosis of HCC that cannot be surgically removed, and the study will assess the safety and efficacy of this combined treatment strategy. The trial is designed to address the limitations of current therapies and improve outcomes for patients facing advanced liver cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants must have diagnosis of HCC that is deemed unsuitable for surgical resection or transplant. Participants may have multiple lesions with a total maximal tumor dimension of \< 20 cm, and no one lesion \> 15 cm. Diagnosis should be confirmed by at least 1 criterion listed below:

  * Histologically or cytologically proven diagnosis of HCC.
  * Typical arterial enhancement and delayed washout on multiphasic CT or MRI.
* Age ≥18 years at the time of signing informed consent document.
* ECOG performance status 0-1.
* Barcelona Clinic Liver Cancer (BCLC) stages Intermediate (B) or Advanced (C).
* Child-Pugh score 5-6 liver function within 28 days of study registration.
* Documented virology status of hepatitis B virus (HBV), as confirmed by screening HBV serology test.
* Documented virology status of hepatitis C virus (HCV), as confirmed by screening HCV serology test.
* Ability to understand and the willingness to sign a written informed consent document
* Adequate bone marrow, liver, and renal function within 4 weeks before study registration

  * Hemoglobin ≥ 9.0 g/dL
  * Absolute neutrophil count (ANC) ≥ 1,000/mm3
  * Platelet count ≥ 50,000/μL
  * Total bilirubin \< 2.5 mg/dL
  * Serum albumin \>2.8 g/dL
  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper limit of normal (ULN)
  * Prothrombin time ≤ 6 seconds prolonged
  * Serum creatinine ≤ 1.5 mg/dL

Exclusion Criteria:

* Prior invasive malignancy unless disease free for a minimum of 2 years
* Prior radiotherapy to the region of the liver that would result in overlap of radiation therapy fields
* Prior selective internal radiotherapy/hepatic arterial yttrium therapy, at any time
* Untreated active hepatitis B or hepatitis C
* Moderate to severe or intractable ascites
* Presence of distant metastases that cannot be encompassed by proton radiotherapy
* Untreated or incomplete treated esophageal or gastric varices
* Severe, active co-morbidity, defined as follows:

  * Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration
  * Myocardial infarction within the last 6 months prior to study entry
  * Acute bacterial or fungal infection requiring intravenous antibiotics within 28 days prior to study entry
  * A bleeding episode within 6 months prior to study entry due to any cause.
  * Thrombolytic therapy within 28 days prior to study entry.
  * Known bleeding or clotting disorder.
  * Uncontrolled psychotic disorder
* Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
* Prior solid organ transplantation.
* Prior or active autoimmune disease (AID) including autoimmune hepatitis, inflammatory bowel disease, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren's syndrome, Guillain-Barre syndrome, and multiple sclerosis.
* Prior or active thrombotic or bleeding disorders, hemoptysis, cerebral vascular accident, significant cardiac disease (ischemic or congestive heart failure), or gastrointestinal perforation.
* Inability to treat all sites of disease by proton radiotherapy (such as extrahepatic metastases or massive liver tumors whereby the liver constraints \[ULV/SLV \>40%\] cannot be met for covering all sites of liver tumors using proton radiotherapy.)
* Known HIV infection.

Where it's running

• Chang Gung Memorial Hospital at Linkou
  Taoyuan City, Taiwan, Taiwan Recruiting

Study contacts

• Study coordinator: Rodney Cheng-En Hsieh, MD, PhD
• Email: rodney445@gmail.com
• Phone: 88633281200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood biomarkers to predict response to atezolizumab plus bevacizumab in hepatocellular carcinoma

  This study tests whether blood-based biomarkers can predict which patients with advanced liver cancer will respond to first-line atezolizumab plus bevacizumab.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07734857

• AI system to predict response to Atezolizumab-Bevacizumab in unresectable liver cancer

  This study looks at whether an artificial intelligence tool can predict how patients with unresectable hepatocellular carcinoma will respond to atezolizumab-bevacizumab.

  Recruiting First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT07495735

• TIPS benefits for people with hepatocellular carcinoma taking Tecentriq (atezolizumab) plus Avastin (bevacizumab) as first-line therapy.

  This study will try to see if placing a TIPS device helps people with advanced or unresectable hepatocellular carcinoma who are starting first-line treatment with Tecentriq plus Avastin.

  Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Düsseldorf, North Rhine-Westphalia · NCT07365930

• Bevacizumab followed by atezolizumab versus both together for advanced hepatocellular carcinoma with MASLD

  This test will see if giving bevacizumab first and then atezolizumab works better than giving both at the same time for adults with advanced hepatocellular carcinoma and metabolic-associated steatotic liver disease (MASLD).

  Recruiting Phase 2/3 Eastern Hepatobiliary Surgery Hospital · Shanghai, Shanghai Municipality · NCT07285850

• Using fecal microbiota transplantation to try to restore response to atezolizumab and bevacizumab in people with unresectable hepatocellular carcinoma.

  This will try whether giving a fecal microbiota transplant and then restarting atezolizumab plus bevacizumab can restore treatment response in adults with unresectable HCC who progressed early on those drugs.

  Recruiting Phase 2 IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, BO · NCT07276100

• Trimipramine with atezolizumab and bevacizumab for recurrent glioblastoma

  Researchers will try whether adding the antidepressant trimipramine to the immunotherapy atezolizumab plus bevacizumab helps people with recurrent glioblastoma.

  Recruiting at 7 sites Phase 2 Centre Hospitalier Universitaire Vaudois · Basel, Basel and 6 other locations · NCT07263438

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.